Biogen Idec Inc., the world’s largest maker of medicines for multiple sclerosis, declined in early trading after the drugmaker forecast 2012 earnings that were less than analysts estimated.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
